Birgitte S. Wulff
Birgitte S. Wulff has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Søren Østergaard
Novo Nordisk A/S, Global Research Technologies, Novo Nordisk Research Park, Maaloev, Denmark
4 shared publications - Johan F. Paulsson
Global Drug Discovery Novo Nordisk Research Park 2760 Maaloev Denmark
3 shared publications - Marina Kjærgaard Gerstenberg
Global Drug Discovery Novo Nordisk Research Park 2760 Maaloev Denmark
3 shared publications Jane Spetzler
Global Research Technologies, Novo Nordisk A/S, Novo Nordisk Research Park, Maaloev, Denmark
2 shared publicationsKirsten Raun
Global Research Technologies, Novo Nordisk A/S, Novo Nordisk Research Park, Maaloev, Denmark
2 shared publicationsAdam Paul Chambers
Novo Nordisk A/S Måløv Denmark
1 shared publication
Latest Publications
- Open Access
Long‐acting PYY3−36 analogue with semaglutide for obesity: from preclinical assessment through randomized clinical studies
Objective: The hormone peptide YY (PYY; cleaved into Y2‐selective form PYY3‐36) is an attractive candidate for use as a complementary pharmacotherapy for obesity along with glucagon‐like peptide‐1 (GLP‐1) receptor agonists. This series of studies investigated a novel long‐acting PYY3‐36 analogue (PYY1875) alone and as an add‐on to semaglutide for treatment of obesity.Methods: Weight loss and food intake were first investigated in obese male rats, followed by phase 1 and 2 clinical studies investigating efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of PYY1875 as monotherapy and in combination with semaglutide in participants with overweight or obesity.Results: PYY1875 induced additional body weight loss in semaglutide‐treated obese rats. In the phase 1 study, all doses of PYY1875 alone and coadministered with semaglutide were tolerated. In the phase 2 study, a modest but not clinically meaningful treatment effect of PYY1875 1.0 mg versus placebo as an add‐on to semaglutide 2.4 mg was observed. However, gastrointestinal‐related adverse events were common with the 1.0‐mg PYY1875 dose, and the 2.0‐mg PYY1875 dose escalation regimen was not tolerated (both as add‐ons to semaglutide).Conclusions: PYY1875 showed modest efficacy as an add‐on to semaglutide for weight management in people with obesity, but the treatment was not well tolerated.
Open AccessLong‐acting PYY3−36 analogue with semaglutide for obesity: from preclinical assessment through randomized clinical studies
Objective: The hormone peptide YY (PYY; cleaved into Y2‐selective form PYY3‐36) is an attractive candidate for use as a complementary pharmacotherapy for obesity along with glucagon‐like peptide‐1 (GLP‐1) receptor agonists. This series of studies investigated a novel long‐acting PYY3‐36 analogue (PYY1875) alone and as an add‐on to semaglutide for treatment of obesity.Methods: Weight loss and food intake were first investigated in obese male rats, followed by phase 1 and 2 clinical studies investigating efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of PYY1875 as monotherapy and in combination with semaglutide in participants with overweight or obesity.Results: PYY1875 induced additional body weight loss in semaglutide‐treated obese rats. In the phase 1 study, all doses of PYY1875 alone and coadministered with semaglutide were tolerated. In the phase 2 study, a modest but not clinically meaningful treatment effect of PYY1875 1.0 mg versus placebo as an add‐on to semaglutide 2.4 mg was observed. However, gastrointestinal‐related adverse events were common with the 1.0‐mg PYY1875 dose, and the 2.0‐mg PYY1875 dose escalation regimen was not tolerated (both as add‐ons to semaglutide).Conclusions: PYY1875 showed modest efficacy as an add‐on to semaglutide for weight management in people with obesity, but the treatment was not well tolerated.
- Open Access
- 27 October 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-15
The effect of fatty diacid acylation of human PYY3-36 on Y2 receptor potency and half-life in minipigs
Peptides are notoriously known to display very short in vivo half-lives often measured in minutes which in many cases greatly reduces or eliminates sufficient in vivo efficacy. To obtain long half-lives allowing for up to once-weekly dosing regimen, fatty acid acylation (lipidation) have been used to non-covalently associate the peptide to serum albumin thus serving as a circulating depot. This approach is generally considered in the scientific and patent community as a standard approach to protract almost any given peptide. However, it is not trivial to prolong the half-life of peptides by lipidation and still maintain high potency and good formulation properties. Here we show that attaching a fatty acid to the obesity-drug relevant peptide PYY3-36 is not sufficient for long pharmacokinetics (PK), since the position in the backbone, but also type of fatty acid and linker strongly influences PK and potency. Furthermore, understanding the proteolytic stability of the backbone is key to obtain long half-lives by lipidation, since backbone cleavage still occurs while associated to albumin. Having identified a PYY analogue with a sufficient half-life, we show that in combination with a GLP-1 analogue, liraglutide, additional weight loss can be achieved in the obese minipig model.
- 27 October 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-15
Open AccessThe effect of fatty diacid acylation of human PYY3-36 on Y2 receptor potency and half-life in minipigs
Peptides are notoriously known to display very short in vivo half-lives often measured in minutes which in many cases greatly reduces or eliminates sufficient in vivo efficacy. To obtain long half-lives allowing for up to once-weekly dosing regimen, fatty acid acylation (lipidation) have been used to non-covalently associate the peptide to serum albumin thus serving as a circulating depot. This approach is generally considered in the scientific and patent community as a standard approach to protract almost any given peptide. However, it is not trivial to prolong the half-life of peptides by lipidation and still maintain high potency and good formulation properties. Here we show that attaching a fatty acid to the obesity-drug relevant peptide PYY3-36 is not sufficient for long pharmacokinetics (PK), since the position in the backbone, but also type of fatty acid and linker strongly influences PK and potency. Furthermore, understanding the proteolytic stability of the backbone is key to obtain long half-lives by lipidation, since backbone cleavage still occurs while associated to albumin. Having identified a PYY analogue with a sufficient half-life, we show that in combination with a GLP-1 analogue, liraglutide, additional weight loss can be achieved in the obese minipig model.
- 15 January 2021
- Published by Wiley in Angewandte Chemie
- Vol. 133 (15) , 8349-8356
The Design of a GLP‐1/PYY Dual Acting Agonist
The two gut hormones GLP‐1 and PYY3–36, which are both secreted from the L‐cells upon food stimuli, have a stronger inhibitory effect on food intake when they are combined, compared to their individual effects as single agonists. Although they are not homologous and share no sequence similarity, we show that a GLP‐1 analogue can be designed to exhibit potent activity on both the Y2 and GLP‐1 receptors. Dual acting hybrid analogues were realized by designing truncated and potent Y2 receptor PYY analogues, followed by integrating the critical residues into GLP‐1. In this study, we show that one of these dual acting agonists acutely reduces food intake significantly more than the respective mono‐agonist counterparts.
- 15 January 2021
- Published by Wiley in Angewandte Chemie
- Vol. 133 (15) , 8349-8356
The Design of a GLP‐1/PYY Dual Acting Agonist
The two gut hormones GLP‐1 and PYY3–36, which are both secreted from the L‐cells upon food stimuli, have a stronger inhibitory effect on food intake when they are combined, compared to their individual effects as single agonists. Although they are not homologous and share no sequence similarity, we show that a GLP‐1 analogue can be designed to exhibit potent activity on both the Y2 and GLP‐1 receptors. Dual acting hybrid analogues were realized by designing truncated and potent Y2 receptor PYY analogues, followed by integrating the critical residues into GLP‐1. In this study, we show that one of these dual acting agonists acutely reduces food intake significantly more than the respective mono‐agonist counterparts.
- 15 January 2021
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 60 (15) , 8268-8275
The Design of a GLP‐1/PYY Dual Acting Agonist
The two gut hormones GLP‐1 and PYY3–36, which are both secreted from the L‐cells upon food stimuli, have a stronger inhibitory effect on food intake when they are combined, compared to their individual effects as single agonists. Although they are not homologous and share no sequence similarity, we show that a GLP‐1 analogue can be designed to exhibit potent activity on both the Y2 and GLP‐1 receptors. Dual acting hybrid analogues were realized by designing truncated and potent Y2 receptor PYY analogues, followed by integrating the critical residues into GLP‐1. In this study, we show that one of these dual acting agonists acutely reduces food intake significantly more than the respective mono‐agonist counterparts.
- 15 January 2021
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 60 (15) , 8268-8275
The Design of a GLP‐1/PYY Dual Acting Agonist
The two gut hormones GLP‐1 and PYY3–36, which are both secreted from the L‐cells upon food stimuli, have a stronger inhibitory effect on food intake when they are combined, compared to their individual effects as single agonists. Although they are not homologous and share no sequence similarity, we show that a GLP‐1 analogue can be designed to exhibit potent activity on both the Y2 and GLP‐1 receptors. Dual acting hybrid analogues were realized by designing truncated and potent Y2 receptor PYY analogues, followed by integrating the critical residues into GLP‐1. In this study, we show that one of these dual acting agonists acutely reduces food intake significantly more than the respective mono‐agonist counterparts.
- Open Access
- 1 February 2019
- Published by Elsevier in Neuropeptides
- Vol. 73, 89-95
PYY(3-36) and exendin-4 reduce food intake and activate neuronal circuits in a synergistic manner in mice
- 1 February 2019
- Published by Elsevier in Neuropeptides
- Vol. 73, 89-95
Open AccessPYY(3-36) and exendin-4 reduce food intake and activate neuronal circuits in a synergistic manner in mice
- 24 February 2012
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 55 (5) , 1969-1977
Identification and in Vivo and in Vitro Characterization of Long Acting and Melanocortin 4 Receptor (MC4-R) Selective α-Melanocyte-Stimulating Hormone (α-MSH) Analogues
We report in vitro and in vivo data of new α-melanocyte-stimulating hormone (α-MSH) analogues which are N-terminal modified with a long chain fatty acid derivative. While keeping the pharmacophoric motif (d-Phe-Arg-Trp) fixed, we tried to improve selectivity and physicochemical parameters like solubility and stability of these analogues by replacing amino acids further away from the motif. Receptor specific changes in binding affinity to the melanocortin receptors were observed between the acetyl derivatives and the fatty acid analogues. Furthermore, amino acids at the N-terminal of α-MSH (Ser-Tyr-Ser) not considered to be part of the pharmacophore were found to have an influence on the MC4/MC1 receptor selectivity. While the acetyl analogues have an in vivo effect for around 7 h, the long chain fatty acid analogues have an effect up to 48 h in an acute feeding study in male Sprague–Dawley rats after a single subcutaneous administration.
- 24 February 2012
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 55 (5) , 1969-1977
Identification and in Vivo and in Vitro Characterization of Long Acting and Melanocortin 4 Receptor (MC4-R) Selective α-Melanocyte-Stimulating Hormone (α-MSH) Analogues
We report in vitro and in vivo data of new α-melanocyte-stimulating hormone (α-MSH) analogues which are N-terminal modified with a long chain fatty acid derivative. While keeping the pharmacophoric motif (d-Phe-Arg-Trp) fixed, we tried to improve selectivity and physicochemical parameters like solubility and stability of these analogues by replacing amino acids further away from the motif. Receptor specific changes in binding affinity to the melanocortin receptors were observed between the acetyl derivatives and the fatty acid analogues. Furthermore, amino acids at the N-terminal of α-MSH (Ser-Tyr-Ser) not considered to be part of the pharmacophore were found to have an influence on the MC4/MC1 receptor selectivity. While the acetyl analogues have an in vivo effect for around 7 h, the long chain fatty acid analogues have an effect up to 48 h in an acute feeding study in male Sprague–Dawley rats after a single subcutaneous administration.